Literature DB >> 1000506

The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture.

M Lippman, G Bolan, K Huff.   

Abstract

We have examined five human breast cancer cell lines in continuous tissue culture for androgen responsiveness. One of these cell lines shows a 2- to 4-fold stimulation of thymidine incorporation into DNA, apparent as early as 10 hr following androgen addition to cells incubated in serum-free medium. This stimulation is accompanied by an acceleration in cell replication. Antiandrogens [cyproterone acetate (6-chloro-17alpha-acetate-1,2alpha-methylene-4,6-pregnadiene-3,20-dione) and R2956 (17beta-hydroxy-2,2,17alpha-trimethoxyestra-4,9,11-triene-1-one)] inhibit both protein and DNA synthesis below control levels and block androgen-mediated stimulation. Prolonged incubation (greater than 72 hr) in antiandrogen is lethal. The MCF- cell line contains high-affinity receptors for androgenic steroids demonstrable by sucrose density gradients and competitive protein binding analysis. By cross-competition studies, androgen receptors are distinguishable from estrogen receptors also found in this cell line. Concentrations of steroid that saturate androgen receptor sites in vitro are about 1000 times lower than concentrations that maximally stimulate the cells. Changes in quantity and affinity of androgen binding to intact cells at 37 degrees as compared with usual binding techniques using cytosol preparation at 0 degrees do not explain this difference between dissociation of binding and effect. However, this difference can be explained by conversion of [3H]-5alpha-dihydrotestosterone to 5alpha-androstanediol and more polar metabolites at 37 degrees. An examination of incubation media, cytoplasmic extracts and crude nuclear pellets reveals probable conversion of [3H]testosterone to [3H]-5alpha-dihydrotestosterone. Our data provide compelling evidence that some human breast cancer, at least in vitro, may be androgen dependent.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1000506

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  Down-regulation of androgen receptor by progestins and interference with estrogenic or androgenic stimulation of mammary carcinoma cell growth.

Authors:  R Hackenberg; J Hofmann; G Wolff; F Hölzel; K D Schulz
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  A serum-free medium for the growth of muscle cells in culture.

Authors:  J R Florini; S B Roberts
Journal:  In Vitro       Date:  1979-12

Review 3.  Epidemiology of endocrine-related risk factors for breast cancer.

Authors:  Leslie Bernstein
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

4.  Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cells.

Authors:  Samir Koirala; Lynn N Thomas; Catherine K L Too
Journal:  Mol Endocrinol       Date:  2014-01-16

5.  Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma.

Authors:  Cristina Riva; Emanuele Dainese; Giacomo Caprara; Paolo Cossu Rocca; Giovanni Massarelli; Tibor Tot; Carlo Capella; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

6.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Authors:  R Poulin; D Baker; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872

7.  Influence of estradiol on the total uptake and incorporation of thymidine in human breast cancer (MCF-7) in long-term cell culture. Comparison of autoradiographic and biochemical methods.

Authors:  R Coosen; P W de Jong; F Schwarz
Journal:  Mol Cell Biochem       Date:  1982-02-19       Impact factor: 3.396

8.  Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer.

Authors:  M A Fanelli; L M Vargas-Roig; F E Gago; O Tello; R Lucero De Angelis; D R Ciocca
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor.

Authors:  R Hackenberg; T Hawighorst; A Filmer; A H Nia; K D Schulz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 10.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.